Two tests and one reference [General Sta­tis­tics]

posted by ElMaestro  – Denmark, 2020-08-31 10:23 (231 d 00:49 ago) – Posting: # 21896
Views: 3,467

Hi Brus,

» If one test and two references of different regions are tested in a bioequivalence study, is it necessary a α adjustment?
»
» In my case, we want to demonstrate if the test product is bioequivalent to R1 (European product reference) or if test product is bioequivalent to R2 (Reference product in the United Kingdom).
»
» If I have not misunderstood, in this case, alpha should be penalized, even if they are from different regions and to market in different regions because of the word "OR"?
»
» Is there a way to not penalize alpha? If the "O" is changed to "AND"? Executing two different clinical trials (one for Europe and one for the UK)?

Here's a different way to look at it:
Can the same patient(s) be affected by your two tests? If yes, it is safer to use correction. If no, no correction should be necessary.

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 13 (0 registered, 13 guests [including 4 identified bots]).
Forum time: Monday 11:13 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5